In connection with the above reports, a study was conducted to assess the effect of alirocumab on the incidence of venous thromboembolism, which showed that alirocumab significantly reduces the risk of venous thromboembolism when compared to the group of patients using the placebo, which was associated with a significant decrease in Lp(a) levels after drug administration [62]. Here, LPA is linked to venous thromboembolism.